Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737

Media coverage

• Title	Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
  Media name/outlet	Canadian Life Sciences Database
  Country	Switzerland
  Date	11/30/18
  Persons	Jing Wang

• Title	Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
  Media name/outlet	Biotechgate
  Country	Switzerland
  Date	11/30/18
  Persons	Jing Wang

• Title	Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
  Media name/outlet	BioSpace
  Country	United States
  Date	11/30/18
  Persons	Jing Wang

• Title	Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
  Media name/outlet	PipelineReview
  Country	Spain
  Date	11/30/18
  Persons	Jing Wang

• Title	Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
  Media name/outlet	Canada NewsWire
  Country	Canada
  Date	11/29/18
  Persons	Jing Wang

• Title	Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
  Media name/outlet	PR Newswire
  Country	United States
  Date	11/29/18
  Persons	Jing Wang

• Title	Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
  Media name/outlet	Canada NewsWire
  Country	Canada
  Date	11/29/18
  Persons	Jing Wang

• Title	Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
  Media name/outlet	PR Newswire
  Country	United States
  Date	11/29/18
  Persons	Jing Wang

• Title	Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
  Media name/outlet	Canada NewsWire
  Country	Canada
  Date	11/29/18
  Persons	Jing Wang

• Title	Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
  Media name/outlet	PR Newswire
  Country	United States
  Date	11/29/18
  Persons	Jing Wang

• Title	Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
  Media name/outlet	Nasdaq
  Country	United States
  Date	11/29/18
  Persons	Jing Wang

• Title	Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
  Media name/outlet	India Pharma News
  Country	India
  Date	11/29/18
  Persons	Jing Wang

• Title	Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
  Media name/outlet	TickerTech.com
  Country	United States
  Date	11/29/18
  Persons	Jing Wang

• Title	Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
  Media name/outlet	Stockwatch
  Country	Canada
  Date	11/29/18
  Persons	Jing Wang

• Title	Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
  Media name/outlet	PharmiWeb
  Country	United Kingdom
  Date	11/29/18
  Persons	Jing Wang

• Title	Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
  Media name/outlet	Finanzen.ch
  Country	Switzerland
  Date	11/29/18
  Persons	Jing Wang

• Title	Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
  Media name/outlet	Markets Business Insider
  Country	United States
  Date	11/29/18
  Persons	Jing Wang

• Title	Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
  Media name/outlet	Spoke.com
  Country	United States
  Date	11/29/18
  Persons	Jing Wang

• Title	Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
  Media name/outlet	Central Charts
  Country	France
  Date	11/29/18
  Persons	Jing Wang